Last reviewed · How we verify
NCT04726150: CoViDEx
Effect of CoVid-19 (CoronaVirusDisease-19) and Exercise on Myocardial Fibrosis and Ventricular Arrhythmias
trial testing ILR implantation in Covid19 in 85 participants. Completed in 31 October 2022.
31 December 2021
Quick facts
| Lead sponsor | University Hospital, Antwerp |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 85 |
| Start date | 1 April 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 October 2022 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- ILR implantation
Conditions studied
- Covid19 — all drugs for Covid19 →
- Athletes Heart — all drugs for Athletes Heart →
- Myocarditis Viral — all drugs for Myocarditis Viral →
- Ventricular Arrythmia — all drugs for Ventricular Arrythmia →
Sponsor
University Hospital, Antwerp
Who can join
18 and older, any sex, with Covid19 or Athletes Heart. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COVID-19 can cause myocarditis, which can cause myocardial fibrosis. This has been shown to increase mortality and morbidity among athletes. Several efforts have been made to guide sports participation after COVID-19, but not much scientific evidence is present to back-up those guidelines. The current initiative aims gain a heightened insight in this matter.To identify the presence of fibrosis athletes who recovered from COVID-19 will undergo CMR (Cardiac MRI). All athletes will also undergo echocardiography, 5-day Holtermonitoring among others. This will allow to determine whether differences between those with and those without fibrosis are present. If fibrosis is present, athletes will be offered an implantation of a very small monitoring device that will be able to detect arrhythmias with a much higher sensitivity. Also an exercise echocardiography will be performed, to determine the safety of continuation of athletic efforts. Amendment: Recently myocarditis and pericarditis have also been observed after the administration of mRNA-vaccines, specifically after the second dose. The effect of vaccination on exercise capacity is less clear. To investigate this we propose to amend the inclusion criteria for COVIDEX with "athletes undergoing or having undergone COVID vaccination"
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury.
Siripanthong B, Asatryan B, Hanff TC, Chatha SR, et al · · 2022 · cited 73× · PMID 35165665 · DOI 10.1016/j.jacbts.2021.10.011 -
Effect of BNT162b2 mRNA booster vaccination on VO<sub>2</sub> <sub>max</sub> in recreational athletes: A prospective cohort study.
Miljoen H, Bekhuis Y, Roeykens J, Taha K, et al · · 2022 · cited 3× · PMID 36425900 · DOI 10.1002/hsr2.929 -
Low rates of myocardial fibrosis and ventricular arrhythmias in recreational athletes after SARS-CoV-2 infection.
Miljoen H, Favere K, Van De Heyning C, Corteville B, et al · · 2024 · PMID 38628312 · DOI 10.3389/fcvm.2024.1372028
Verify or expand the search:
- PubMed search for NCT04726150
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other University Hospital, Antwerp trials
Trials by the same sponsor.
- NCT07455422 — A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurr · NA · not yet recruiting
- NCT07020715 — A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis · Phase 2 · not yet recruiting
- NCT07443761 — Patients Undergoing Pancreatic Surgery at the Antwerp University Hospital. · active not recruiting
- NCT06372847 — DISE-HNS Effect Study · NA · recruiting
- NCT07189091 — CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04726150 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Antwerp
- Last refreshed: 1 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04726150.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing